AU2015278765B2 - Intermittent dosing of MDM2 inhibitor - Google Patents

Intermittent dosing of MDM2 inhibitor Download PDF

Info

Publication number
AU2015278765B2
AU2015278765B2 AU2015278765A AU2015278765A AU2015278765B2 AU 2015278765 B2 AU2015278765 B2 AU 2015278765B2 AU 2015278765 A AU2015278765 A AU 2015278765A AU 2015278765 A AU2015278765 A AU 2015278765A AU 2015278765 B2 AU2015278765 B2 AU 2015278765B2
Authority
AU
Australia
Prior art keywords
days
mdm2i
time post
injection
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015278765A
Other languages
English (en)
Other versions
AU2015278765A1 (en
Inventor
Stephane FERRETTI
Sebastien Jeay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53510950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015278765(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2015278765A1 publication Critical patent/AU2015278765A1/en
Application granted granted Critical
Publication of AU2015278765B2 publication Critical patent/AU2015278765B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015278765A 2014-06-26 2015-06-25 Intermittent dosing of MDM2 inhibitor Ceased AU2015278765B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017406P 2014-06-26 2014-06-26
US62/017,406 2014-06-26
PCT/IB2015/054792 WO2015198266A1 (en) 2014-06-26 2015-06-25 Intermittent dosing of mdm2 inhibitor

Publications (2)

Publication Number Publication Date
AU2015278765A1 AU2015278765A1 (en) 2017-01-19
AU2015278765B2 true AU2015278765B2 (en) 2018-08-16

Family

ID=53510950

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015278765A Ceased AU2015278765B2 (en) 2014-06-26 2015-06-25 Intermittent dosing of MDM2 inhibitor

Country Status (18)

Country Link
US (6) US20170196866A1 (enExample)
EP (1) EP3160463B1 (enExample)
JP (1) JP6728072B2 (enExample)
KR (3) KR20240110659A (enExample)
CN (2) CN115569197A (enExample)
AU (1) AU2015278765B2 (enExample)
BR (1) BR112016029750A2 (enExample)
CA (1) CA2953079C (enExample)
CL (1) CL2016003295A1 (enExample)
ES (1) ES2856210T3 (enExample)
IL (1) IL249138B (enExample)
MX (1) MX2016017075A (enExample)
PH (1) PH12016502556A1 (enExample)
RU (1) RU2695228C2 (enExample)
SG (1) SG11201609853VA (enExample)
TN (1) TN2016000522A1 (enExample)
TW (1) TW201613576A (enExample)
WO (1) WO2015198266A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN109982702A (zh) 2016-11-15 2019-07-05 诺华股份有限公司 HDM2-p53相互作用抑制剂的剂量及方案
ES2942419T3 (es) * 2017-03-31 2023-06-01 Novartis Ag Dosis y pauta para un inhibidor de la interacción HDM2-p53 en tumores hemáticos
EP3766883B1 (en) * 2018-03-12 2022-09-28 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Imidaxopyrolone compound and application thereof
KR20200134253A (ko) 2018-03-20 2020-12-01 노파르티스 아게 약제학적 병용물
IL319432A (en) * 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
CN112804994A (zh) * 2018-05-25 2021-05-14 卡托斯医疗公司 治疗骨髓增殖性肿瘤的方法
JP2022514280A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー Ｍｄｍ２阻害剤のための延長低用量レジメン
AU2020351324B2 (en) 2019-09-16 2023-08-03 Novartis Ag Use of an MDM2 inhibitor for the treatment of myelofibrosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076786A1 (en) * 2009-12-22 2011-06-30 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2013111105A1 (en) * 2012-01-26 2013-08-01 Novartis Ag Imidazopyrrolidinone compounds
US20140148494A1 (en) * 2010-11-12 2014-05-29 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US20030139373A1 (en) 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
JP5248866B2 (ja) 2005-02-22 2013-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｄｍ２の小分子阻害剤およびその使用
CN102770182B (zh) * 2009-12-22 2014-10-29 诺华股份有限公司 被取代的异喹啉酮类和喹唑酮类
PL2361667T3 (pl) 2010-02-25 2015-07-31 General Electric Technology Gmbh Płuczka wodna i sposób oczyszczania gazu procesowego
KR20130088170A (ko) * 2010-12-16 2013-08-07 로슈 글리카트 아게 비푸코실화 ｃｄ20 항체와 ｍｄｍ2 저해제와의 조합 치료
LT2741824T (lt) 2011-08-11 2017-06-26 Estetra S.P.R.L. Estetrolio panaudojimas kaip skubaus kontraceptiko
EP2793890B1 (en) 2011-12-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
ES2742285T3 (es) 2012-07-31 2020-02-13 Novartis Ag Marcadores asociados con la sensibilidad a inhibidores del doble minuto humano 2 (MDM2)
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
CA2926307C (en) 2013-12-05 2021-11-16 F. Hoffmann-La Roche Ag Novel combination treatment for acute myeloid leukemia (aml)
JP6675313B2 (ja) 2013-12-23 2020-04-01 ノバルティス アーゲー 組合せ医薬
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
JP2018508569A (ja) 2015-02-06 2018-03-29 ユニティ バイオテクノロジー インコーポレイテッド 老化関連状態の治療における化合物および使用
JP6823587B2 (ja) 2015-04-13 2021-02-03 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
TWI804010B (zh) 2015-08-03 2023-06-01 瑞士商諾華公司 作為血液學毒性生物標記之gdf-15
US20190060309A1 (en) 2015-08-28 2019-02-28 Novartis Ag Mdm2 inhibitors and combinations thereof
CN109982702A (zh) 2016-11-15 2019-07-05 诺华股份有限公司 HDM2-p53相互作用抑制剂的剂量及方案
RU2019119213A (ru) 2016-11-22 2020-12-24 Новартис Аг Химический способ получения производных имидазопирролидинона и их промежуточных соединений
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
ES2942419T3 (es) 2017-03-31 2023-06-01 Novartis Ag Dosis y pauta para un inhibidor de la interacción HDM2-p53 en tumores hemáticos
EP3694518A1 (en) 2017-10-12 2020-08-19 Novartis AG Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers
KR20200134253A (ko) 2018-03-20 2020-12-01 노파르티스 아게 약제학적 병용물
AU2019369216B2 (en) 2018-10-30 2022-05-19 Dana-Farber Cancer Institute, Inc. Method of treatment of p53 WT tumors
JP2022514280A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー Ｍｄｍ２阻害剤のための延長低用量レジメン
WO2020202052A1 (en) 2019-04-04 2020-10-08 Novartis Ag Siremadlin succinate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076786A1 (en) * 2009-12-22 2011-06-30 Novartis Ag Substituted isoquinolinones and quinazolinones
US20140148494A1 (en) * 2010-11-12 2014-05-29 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
WO2013111105A1 (en) * 2012-01-26 2013-08-01 Novartis Ag Imidazopyrrolidinone compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIGGINS, B. et al. "Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach" Clinical Cancer Research (May 2014) Vol.20 No.14, pages 3742 to 3752 *

Also Published As

Publication number Publication date
CL2016003295A1 (es) 2017-07-28
US20240261284A1 (en) 2024-08-08
MX2016017075A (es) 2017-05-03
US20210000824A1 (en) 2021-01-07
AU2015278765A1 (en) 2017-01-19
JP6728072B2 (ja) 2020-07-22
KR20240110659A (ko) 2024-07-15
TW201613576A (en) 2016-04-16
EP3160463A1 (en) 2017-05-03
RU2695228C2 (ru) 2019-07-22
SG11201609853VA (en) 2017-01-27
ES2856210T3 (es) 2021-09-27
CA2953079A1 (en) 2015-12-30
US11419870B2 (en) 2022-08-23
CA2953079C (en) 2023-05-02
US20180110779A1 (en) 2018-04-26
KR102462177B1 (ko) 2022-11-04
US20220233530A9 (en) 2022-07-28
CN115569197A (zh) 2023-01-06
JP2017519019A (ja) 2017-07-13
KR20220151027A (ko) 2022-11-11
US20170196866A1 (en) 2017-07-13
US20190209561A1 (en) 2019-07-11
US20230092181A1 (en) 2023-03-23
RU2017102319A3 (enExample) 2019-02-12
IL249138B (en) 2020-09-30
TN2016000522A1 (en) 2018-04-04
BR112016029750A2 (pt) 2017-08-22
PH12016502556A1 (en) 2017-04-17
WO2015198266A1 (en) 2015-12-30
RU2017102319A (ru) 2018-07-26
CN106456635A (zh) 2017-02-22
KR20170017932A (ko) 2017-02-15
EP3160463B1 (en) 2020-10-21
IL249138A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
AU2015278765B2 (en) Intermittent dosing of MDM2 inhibitor
KR102845148B1 (ko) Her2 양성 암의 치료
US20130012465A1 (en) Bibw 2992 for use in the treatment of triple negative breast cancer
TW202216208A (zh) 抗體-藥物結合物及atr抑制劑之組合
KR20130045341A (ko) 암 치료를 위한 저산소증 활성 프로드러그와 항혈관형성제의 투여
CN104116738A (zh) 癌症的治疗
JP2023533485A (ja) 重症型の肺高血圧症の治療方法
JP2015514796A (ja) ２から３０ｍｇ／ｋｇの範囲の用量で癌を治療するのに使用するためのデキサナビノールまたはこの誘導体
JP2021523190A (ja) 腺様嚢胞癌を治療するためのビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組成物
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
US20250262214A1 (en) Intermittent dosing regimen for azenosertib in treating cancer
US20240325370A1 (en) Therapeutic regimens of a degrader of brd9
HK1231740B (en) Intermittent dosing of mdm2 inhibitor
HK1231740A1 (en) Intermittent dosing of mdm2 inhibitor
HK40105125A (zh) Fgfr4抑制剂和胆汁酸螯合剂的组合
WO2022191870A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
HK40009437B (zh) Fgfr4抑制剂和胆汁酸螯合剂的组合

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ INTERMITTENT DOSING OF MDM2 INHIBITOR

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired